Zhi Tong Cai Jing·2025-08-26 12:30Core Viewpoint - Junshi Biosciences (01877) reported a significant increase in revenue and a reduction in net loss for the first half of 2025, indicating improved operational performance and strategic focus on competitive and innovative R&D projects [1] Financial Performance - The company's revenue for the first half of 2025 was approximately 1.168 billion RMB, representing a year-on-year growth of 48.64% [1] - The net loss attributable to shareholders was about 413 million RMB, which narrowed by approximately 36% compared to the previous year [1] - Basic loss per share was 0.42 RMB [1] Revenue Drivers - The revenue growth was primarily driven by the sales income of commercialized drugs, which increased by approximately 42% year-on-year, with sales in the domestic market reaching 954 million RMB [1] Strategic Initiatives - The company is implementing the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan, focusing on R&D projects with competitive advantages and innovation [1] - Efforts are being made to accelerate clinical development, reduce production costs, and enhance sales efficiency to further decrease losses [1]